TN2011000227A1 - Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy - Google Patents
Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapyInfo
- Publication number
- TN2011000227A1 TN2011000227A1 TN2011000227A TN2011000227A TN2011000227A1 TN 2011000227 A1 TN2011000227 A1 TN 2011000227A1 TN 2011000227 A TN2011000227 A TN 2011000227A TN 2011000227 A TN2011000227 A TN 2011000227A TN 2011000227 A1 TN2011000227 A1 TN 2011000227A1
- Authority
- TN
- Tunisia
- Prior art keywords
- salt
- treating
- dabigatran etexilate
- over conventional
- improved efficacy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11341308P | 2008-11-11 | 2008-11-11 | |
US23755909P | 2009-08-27 | 2009-08-27 | |
PCT/EP2009/064874 WO2010055022A1 (fr) | 2008-11-11 | 2009-11-10 | Procédé de traitement ou de prévention de thrombose à l'aide d'étexilate de dabigatran ou d'un sel de celui-ci avec une efficacité accrue par rapport à une thérapie classique par warfarine |
Publications (1)
Publication Number | Publication Date |
---|---|
TN2011000227A1 true TN2011000227A1 (en) | 2012-12-17 |
Family
ID=41463075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TN2011000227A TN2011000227A1 (en) | 2008-11-11 | 2011-05-10 | Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy |
Country Status (21)
Country | Link |
---|---|
US (3) | US20110269799A1 (fr) |
EP (1) | EP2355823A1 (fr) |
JP (1) | JP2013510073A (fr) |
KR (1) | KR20110082564A (fr) |
CN (2) | CN103463083A (fr) |
AR (1) | AR074107A1 (fr) |
AU (1) | AU2009315730A1 (fr) |
BR (1) | BRPI0921354A2 (fr) |
CA (1) | CA2738884A1 (fr) |
CL (1) | CL2011000806A1 (fr) |
CO (1) | CO6382133A2 (fr) |
EA (1) | EA201100755A1 (fr) |
EC (1) | ECSP11011029A (fr) |
IL (1) | IL211853A0 (fr) |
MA (1) | MA32785B1 (fr) |
MX (1) | MX2011004796A (fr) |
NZ (1) | NZ592615A (fr) |
PE (1) | PE20110432A1 (fr) |
TN (1) | TN2011000227A1 (fr) |
TW (1) | TW201031651A (fr) |
WO (1) | WO2010055022A1 (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2738883A1 (fr) | 2008-11-11 | 2010-05-20 | Boehringer Ingelheim International Gmbh | Procede de traitement et de prevention de la thrombose utilisant l'etexilate de dabigatran ou un sel de celui-ci avec un profil de securite ameliore par rapport a la therapie de la warfarine classique |
LT2550966T (lt) * | 2011-07-25 | 2017-01-25 | Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. Kg | Dabigatrano amidoksimo karboksirūgšties esteriai, kaip provaistai, ir jų panaudojimas kaip vaistų |
US10307167B2 (en) | 2012-12-14 | 2019-06-04 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
US10314594B2 (en) | 2012-12-14 | 2019-06-11 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
US10813630B2 (en) | 2011-08-09 | 2020-10-27 | Corquest Medical, Inc. | Closure system for atrial wall |
US20130345262A1 (en) | 2012-06-25 | 2013-12-26 | Boehringer Ingelheim International Gmbh | Method for prevention of stroke |
US20140142689A1 (en) | 2012-11-21 | 2014-05-22 | Didier De Canniere | Device and method of treating heart valve malfunction |
WO2015071841A1 (fr) | 2013-11-12 | 2015-05-21 | Druggability Technologies Holdings Limited | Complexes de dabigatran et ses dérivés, procédé de préparation de ceux-ci et compositions pharmaceutiques contenant ceux-ci |
US9566443B2 (en) | 2013-11-26 | 2017-02-14 | Corquest Medical, Inc. | System for treating heart valve malfunction including mitral regurgitation |
US10842626B2 (en) | 2014-12-09 | 2020-11-24 | Didier De Canniere | Intracardiac device to correct mitral regurgitation |
CN108254216B (zh) * | 2018-03-15 | 2021-04-27 | 攀钢集团西昌钢钒有限公司 | 一种高炉槽的矿料取样方法、装置及可读存储介质 |
US20220175748A1 (en) * | 2019-03-06 | 2022-06-09 | University Of Rochester | Anticoagulant compositions and uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6555581B1 (en) * | 2001-02-15 | 2003-04-29 | Jones Pharma, Inc. | Levothyroxine compositions and methods |
US20060222640A1 (en) * | 2005-03-29 | 2006-10-05 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for treatment of thrombosis |
JP2009543842A (ja) * | 2006-07-17 | 2009-12-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 心臓血管分野における直接トロンビン阻害薬のための新規適応 |
-
2009
- 2009-11-10 NZ NZ592615A patent/NZ592615A/xx not_active IP Right Cessation
- 2009-11-10 AR ARP090104347A patent/AR074107A1/es unknown
- 2009-11-10 MX MX2011004796A patent/MX2011004796A/es not_active Application Discontinuation
- 2009-11-10 CN CN2013102966233A patent/CN103463083A/zh active Pending
- 2009-11-10 WO PCT/EP2009/064874 patent/WO2010055022A1/fr active Application Filing
- 2009-11-10 CN CN2009801448169A patent/CN102209546A/zh active Pending
- 2009-11-10 PE PE2011001003A patent/PE20110432A1/es not_active Application Discontinuation
- 2009-11-10 EA EA201100755A patent/EA201100755A1/ru unknown
- 2009-11-10 AU AU2009315730A patent/AU2009315730A1/en not_active Abandoned
- 2009-11-10 JP JP2011535125A patent/JP2013510073A/ja active Pending
- 2009-11-10 US US13/128,460 patent/US20110269799A1/en not_active Abandoned
- 2009-11-10 TW TW098138140A patent/TW201031651A/zh unknown
- 2009-11-10 KR KR1020117010632A patent/KR20110082564A/ko not_active Application Discontinuation
- 2009-11-10 BR BRPI0921354A patent/BRPI0921354A2/pt not_active IP Right Cessation
- 2009-11-10 CA CA2738884A patent/CA2738884A1/fr not_active Abandoned
- 2009-11-10 EP EP09755873A patent/EP2355823A1/fr not_active Withdrawn
-
2010
- 2010-06-17 US US12/817,369 patent/US20100322870A1/en not_active Abandoned
-
2011
- 2011-03-22 IL IL211853A patent/IL211853A0/en unknown
- 2011-04-12 CL CL2011000806A patent/CL2011000806A1/es unknown
- 2011-05-04 EC EC2011011029A patent/ECSP11011029A/es unknown
- 2011-05-10 TN TN2011000227A patent/TN2011000227A1/fr unknown
- 2011-05-11 CO CO11058058A patent/CO6382133A2/es not_active Application Discontinuation
- 2011-05-11 MA MA33833A patent/MA32785B1/fr unknown
-
2012
- 2012-07-06 US US13/543,080 patent/US20120277269A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MA32785B1 (fr) | 2011-11-01 |
AU2009315730A1 (en) | 2010-05-20 |
TW201031651A (en) | 2010-09-01 |
AR074107A1 (es) | 2010-12-22 |
JP2013510073A (ja) | 2013-03-21 |
CO6382133A2 (es) | 2012-02-15 |
MX2011004796A (es) | 2011-05-30 |
PE20110432A1 (es) | 2011-07-16 |
EA201100755A1 (ru) | 2011-12-30 |
ECSP11011029A (es) | 2011-06-30 |
WO2010055022A1 (fr) | 2010-05-20 |
US20120277269A1 (en) | 2012-11-01 |
CA2738884A1 (fr) | 2010-05-20 |
US20110269799A1 (en) | 2011-11-03 |
NZ592615A (en) | 2013-06-28 |
CL2011000806A1 (es) | 2011-11-11 |
CN103463083A (zh) | 2013-12-25 |
KR20110082564A (ko) | 2011-07-19 |
EP2355823A1 (fr) | 2011-08-17 |
BRPI0921354A2 (pt) | 2019-09-24 |
US20100322870A1 (en) | 2010-12-23 |
CN102209546A (zh) | 2011-10-05 |
IL211853A0 (en) | 2011-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TN2011000227A1 (en) | Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy | |
TN2011000228A1 (en) | Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy | |
NO20074999L (no) | Metode og preparat for behandling av perifere vaskulaere sykdommer | |
NO20065847L (no) | Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase | |
PL1933833T3 (pl) | Terapia do leczenia pęcherza nadreaktywnego | |
WO2010044585A3 (fr) | Composes de piperidine, composition pharmaceutique les contenant et utilisation associee | |
EA201691336A1 (ru) | Способ лечения фибрилляции предсердий | |
MX354535B (es) | TRATAMIENTO DE INFARTO DE MIOCARDIO USANDO ANTAGONISTAS DE TGF-ß. | |
WO2009114089A3 (fr) | Utilisation de fullerenes pour augmenter et stimuler la croissance capillaire | |
NZ592613A (en) | Method for treating or preventing thrombosis using >150 mg to 300 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy | |
AU7040201A (en) | A new use for deferiprone | |
WO2009155070A3 (fr) | Compositions et procédés pour le traitement d’inflammation et de lésions hyperkératotiques | |
TW200503666A (en) | Treatment of type 1 diabetes with pde5 inhibitors | |
EA200901062A1 (ru) | Использование ингибиторов растворимой эпоксидгидролазы для предотвращения и лечения метаболического синдрома и соответствующих расстройств | |
DE602006020838D1 (de) | Medikamente zur prävention oder behandlung von herzversagen mit einem anticholinergikum | |
MX2011012538A (es) | Terapia de combinacion para el tratamiento del mieloma multiple. | |
UA105645C2 (uk) | Застосування етексилату дабігатрану, необов'язково у формі фармацевтично прийнятної солі, для запобігання інсульту у пацієнта, що страждає від миготливої аритмії | |
UA104158C2 (ru) | Профилактика инсульта у пациента, который страдает мигающей аритмией, с использованием этексилата дабигатрана | |
WO2008016665A3 (fr) | Composés et méthodes de traitement de troubles médiés par flt3 | |
WO2007054725A3 (fr) | Produit compose | |
WO2006042277A3 (fr) | Compositions a liberation prolongee d'inhibiteurs de pompes a protons | |
WO2011156900A3 (fr) | Composés, compositions et procédés pour traiter la sclérose en plaques | |
MY156431A (en) | Methods of treating proliferative skin diseases using carbazole derivatives | |
WO2013177478A3 (fr) | Méthode de traitement | |
NZ625506A (en) | Compositions for treatment of heart failure in dogs. |